These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11839371)

  • 1. Reactivity of serotonin in whole blood.
    Mulder EJ; Anderson GM; Kema IP; Minderaa RB
    Biol Psychiatry; 2002 Feb; 51(3):266-8. PubMed ID: 11839371
    [No Abstract]   [Full Text] [Related]  

  • 2. Reactivity of serotonin in whole blood: relationship with drug response in obsessive-compulsive disorder.
    Humble M; Bejerot S; Bergqvist PB; Bengtsson F
    Biol Psychiatry; 2001 Feb; 49(4):360-8. PubMed ID: 11239907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paroxetine for treatment of obsessive-compulsive disorder and comorbid stuttering.
    Murray MG; Newman RM
    Am J Psychiatry; 1997 Jul; 154(7):1037. PubMed ID: 9210761
    [No Abstract]   [Full Text] [Related]  

  • 4. Obsessive-compulsive spectrum disorders: effective treatment with paroxetine.
    Ravindran AV; Lapierre YD; Anisman H
    Can J Psychiatry; 1999 Oct; 44(8):805-7. PubMed ID: 10566112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obsessive-compulsive disorder: implications of the efficacy of an SSRI, paroxetine.
    Ninan PT
    Psychopharmacol Bull; 2003; 37 Suppl 1():89-96. PubMed ID: 14566204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clozapine and paroxetine in the treatment of schizophrenia with obsessive-compulsive features.
    Strous RD; Patel JK; Zimmet S; Green AI
    Am J Psychiatry; 1999 Jun; 156(6):973-4. PubMed ID: 10360153
    [No Abstract]   [Full Text] [Related]  

  • 8. Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology.
    Agid O; Lerer B
    J Clin Psychiatry; 1999 Jan; 60(1):55-6. PubMed ID: 10074882
    [No Abstract]   [Full Text] [Related]  

  • 9. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial.
    Denys D; Van Nieuwerburgh F; Deforce D; Westenberg HG
    J Clin Psychiatry; 2007 May; 68(5):747-53. PubMed ID: 17503984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of kleptomania with paroxetine.
    Kraus JE
    J Clin Psychiatry; 1999 Nov; 60(11):793. PubMed ID: 10584771
    [No Abstract]   [Full Text] [Related]  

  • 11. Obsessive-compulsive disorder following cavernous sinus thrombosis.
    Garyfallos G; Papazisis G; Katsigiannopoulos K; Bozikas VP; Adamopoulou A
    J Neuropsychiatry Clin Neurosci; 2009; 21(4):473-4. PubMed ID: 19996263
    [No Abstract]   [Full Text] [Related]  

  • 12. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.
    Denys D; van der Wee N; van Megen HJ; Westenberg HG
    J Clin Psychopharmacol; 2003 Dec; 23(6):568-75. PubMed ID: 14624187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder.
    Hollander E; Dell'Osso B
    Int Clin Psychopharmacol; 2006 May; 21(3):189-91. PubMed ID: 16528143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of social phobia with obsessive-compulsive symptoms improved by paroxetine in combination with risperidone.
    Yamauchi K; Ohta K; Taniguchi T; Ohmori T
    Gen Hosp Psychiatry; 2004; 26(3):242-3. PubMed ID: 15121355
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine.
    Hollander E; Allen A; Steiner M; Wheadon DE; Oakes R; Burnham DB;
    J Clin Psychiatry; 2003 Sep; 64(9):1113-21. PubMed ID: 14628989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paroxetine and its uses in psychiatry.
    Bell C; Nutt D
    Hosp Med; 1999 May; 60(5):353-6. PubMed ID: 10396411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Selective serotonin reuptake inhibitors in treatment of compulsive symptoms within the scope of schizophrenia].
    Scholl HP; Kasper S; Danos P; Höflich G; Möller HJ
    Nervenarzt; 1994 Jul; 65(7):478-81. PubMed ID: 7800092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder.
    Moore GJ; MacMaster FP; Stewart C; Rosenberg DR
    J Am Acad Child Adolesc Psychiatry; 1998 Jun; 37(6):663-7. PubMed ID: 9628087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of treatment response in pediatric obsessive-compulsive disorder.
    Grados MA; Ginsburg GS; Drake KL; Kingery JN
    J Am Acad Child Adolesc Psychiatry; 2009 May; 48(5):573-574. PubMed ID: 19395904
    [No Abstract]   [Full Text] [Related]  

  • 20. Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients.
    Kamijima K; Murasaki M; Asai M; Higuchi T; Nakajima T; Taga C; Matsunaga H
    Psychiatry Clin Neurosci; 2004 Aug; 58(4):427-33. PubMed ID: 15298657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.